MicroRNA-483 amelioration of experimental pulmonary hypertension

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Pulmonary Hypertension Research

Background:

• Endothelial dysfunction is a key factor in pulmonary arterial hypertension (PAH) pathogenesis.
• MicroRNAs (miRNAs) are emerging as potential therapeutic targets.
• Lower miR-483 levels correlate with idiopathic pulmonary arterial hypertension (IPAH) severity.

Purpose of the Study:

• To investigate the role of miR-483 in PAH.
• To explore the therapeutic potential of miR-483 in experimental pulmonary hypertension (PH).

Main Methods:

• RNA sequencing and bioinformatics analysis to identify miR-483 targets.
• In vitro studies involving endothelial cells (ECs) with miR-483 overexpression or inhibition.
• In vivo studies using rat models of PH (monocrotaline or Sugen + hypoxia) with EC-specific miR-483 overexpression or inhaled miR-483 lentivirus.

Main Results:

• miR-483 targets multiple PAH-related genes including TGF-β, TGFBR2, β-catenin, CTGF, IL-1β, and ET-1.
• Overexpression of miR-483 in ECs inhibited inflammatory and fibrogenic responses.
• EC-specific miR-483 overexpression or inhaled miR-483 ameliorated PH and reduced right ventricular hypertrophy in rats.

Conclusions:

• PAH is associated with decreased miR-483 levels.
• miR-483 demonstrates therapeutic potential for experimental PH by inhibiting multiple adverse pathways.
• Restoring miR-483 may offer a novel therapeutic strategy for PAH.